Press Releases

Endonovo Therapeutics Announces collaborating with a Stanford University sponsored Orthopedic Shoulder and Knee Study

Download PDF

Los Angeles, CA, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced Endonovo Therapeutics is collaborating with a Stanford University sponsored Orthopedic Shoulder and Knee Study to determine benefits of Endonovo's tPEMF SofPulse® on pain, medication levels and physical function post-operatively.

The Stanford University study official title is “A Pilot Prospective, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Pulsed Electromagnetic Field (PEMF) Therapy in Decreasing Post-Operative Pain Following Orthopedic Surgery.” The Orthopedic focused study will evaluate 76 patients with Active and Sham Comparator groups, measured by visual analog scale (VAS), at 10 days after and will allow surgeons to determine the efficacy of Endonovo's SofPulse® tPEMF portable device postoperatively. Board certified Orthopedic surgeon, Dr. Geoffrey D. Abrams, is the key investigator and will be conducting the study.

Endonovo's SofPulse® tPEMF portable device is FDA cleared, non-invasive, drug-free non-opioid treatment for postoperative pain and edema presently being adopted for use in major hospitals and clinics nationwide. Endonovo Therapeutics collaboration and participation on multiple efficacy studies, clinical evaluations and adaption by nationwide hospitals will further show the efficacy and effectiveness on PEMF SofPulse® treatments and therapy. 

Endonovo CMO, Dr. Nev Zubcevik DO, “The study will allow surgeons to determine if PEMF SofPulse® therapy is beneficial in reducing patient-reported post-operative pain. Surgeons will be able to make observations on the amount of pain medication taken daily and the physical function outcome scores after surgery and PEMF treatment.”. Results of the study will be published as detailed on  Dr. Zubcevik continued “Past published clinical efficacy studies for tPEMF SofPulse® have shown 2.2X reduction of post-op use of narcotics at 48 hours, 300% reduction of pain scores which relates to nearly a three times faster reduction in the need for pain medication post-op and 275% reduction in inflammation and swelling at 18 hours postoperatively.” 

About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of noninvasive wearable Electroceuticals® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki


Source: Endonovo Therapeutics, Inc.